Company / PP&E (Net)
Compass Therapeutics, Inc. PP&E (Net) History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$353.0K
FY2024
5-year range
$353.0K / $2.2M
FY2020-FY2024
Trend
-60.7%
vs FY2023
Sector context
#175 of 195
Health Care
What the data says
Among 195 Health Care companies, Compass Therapeutics, Inc. is in the bottom 10% for pp&e (net). PP&E (Net) has declined for 3 consecutive years, from $2M in FY2021 to $353,000 in FY2024.
Based on SEC 10-K filings.
$353,000 in FY2024 with a 5-year CAGR of -37.7%.
Declined from $2M to $353,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -46.0%
- 5-Year CAGR
- -37.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 195This company $353.0K Sector average $771.3M
▼
-100.0% below sector average
Key checks
Key Insights
- Compass Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of -37.7%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 60.7% year-over-year.
- Ranks #175 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $353.0K | -60.7% |
| FY2023 | $898.0K | -42.7% |
| FY2022 | $1.6M | -30.1% |
| FY2021 | $2.2M | +99.2% |
| FY2020 | $1.1M | -70.0% |
| FY2019 | $3.8M | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026